These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16823094)

  • 1. Molecular modeling studies of the binding characteristics of phosphates to sevelamer hydrochloride--assessing a novel technique to reduce phosphates contamination.
    Parker R; Odukale AA; Fisher D; Batich C; Ross E; Edwards J
    Int J Environ Res Public Health; 2006 Jun; 3(2):202-8. PubMed ID: 16823094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic and thermodynamic evaluation of phosphate ions binding onto sevelamer hydrochloride.
    Elsiddig R; Hughes H; Owens E; O' Reilly NJ; O'Grady D; McLoughlin P
    Int J Pharm; 2014 Oct; 474(1-2):25-32. PubMed ID: 25102115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel dosage forms and regimens for sevelamer-based phosphate binders.
    Duggal A; Hanus M; Zhorov E; Dagher R; Plone MA; Goldberg J; Burke SK
    J Ren Nutr; 2006 Jul; 16(3):248-52. PubMed ID: 16825030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
    Taniguchi K; Kakuta H
    Eur J Pharmacol; 2015 Nov; 766():129-34. PubMed ID: 26452517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
    Autissier V; Damment SJ; Henderson RA
    J Pharm Sci; 2007 Oct; 96(10):2818-27. PubMed ID: 17497733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phosphate binding assay for sevelamer hydrochloride by ion chromatography.
    Mazzeo JR; Peters RM; Hanus MR; Chen X; Norton KA
    J Pharm Biomed Anal; 1999 May; 19(6):911-5. PubMed ID: 10698557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of poly(allylamine hydrochloride) hydrogel crosslinking density on its thermal and phosphate binding properties.
    Elsiddig R; O'Reilly NJ; Hudson SP; Owens E; Hughes H; O'Grady D; McLoughlin P
    Int J Pharm; 2022 Jun; 621():121806. PubMed ID: 35526696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endotoxin-binding affinity of sevelamer hydrochloride.
    Perianayagam MC; Jaber BL
    Am J Nephrol; 2008; 28(5):802-7. PubMed ID: 18506105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
    Wilkes BM; Reiner D; Kern M; Burke S
    Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.
    Burke SK; Slatopolsky EA; Goldberg DI
    Nephrol Dial Transplant; 1997 Aug; 12(8):1640-4. PubMed ID: 9269642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics.
    Burke S; Amin N; Incerti C; Plone M; Watson N
    J Clin Pharmacol; 2001 Feb; 41(2):193-8. PubMed ID: 11210401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography.
    Swearingen RA; Chen X; Petersen JS; Riley KS; Wang D; Zhorov E
    J Pharm Biomed Anal; 2002 Jun; 29(1-2):195-201. PubMed ID: 12062678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers.
    Burke SK; Amin NS; Incerti C; Plone MA; Lee JW
    J Clin Pharmacol; 2001 Feb; 41(2):199-205. PubMed ID: 11210402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.
    Mahdavi H; Kuizon BD; Gales B; Wang HJ; Elashoff RM; Salusky IB
    Pediatr Nephrol; 2003 Dec; 18(12):1260-4. PubMed ID: 14586677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient acid exposure increases sevelamer HCl phosphate binding.
    Ross EA; Scott WE; Odukale AA; Alba NA; Batich CD
    J Pharm Sci; 2007 Aug; 96(8):2154-60. PubMed ID: 17506513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder.
    Nagano N; Miyata S; Obana S; Eto N; Fukushima N; Burke SK; Wada M
    Nephron; 2001 Nov; 89(3):321-8. PubMed ID: 11598397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of sevelamer hydrochloride in patients with end-stage renal disease: a retrospective study.
    Alam S; Hussain A; Daiwajna R; Tan J
    Singapore Med J; 2013 May; 54(5):263-6. PubMed ID: 23716151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.
    Nagano N; Miyata S; Obana S; Ozai M; Kobayashi N; Fukushima N; Burke SK; Wada M
    Nephrol Dial Transplant; 2001 Sep; 16(9):1870-8. PubMed ID: 11522872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric pH, sevelamer hydrochloride and omeprazole.
    Capitanini A; Lupi A; Osteri F; Petrone I; Del Corso C; Straniti M; Gallieni M; Rossi A
    Clin Nephrol; 2005 Oct; 64(4):320-2. PubMed ID: 16240906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The crossover comparative trial of calcium acetate versus sevelamer hydrochloride (Renagel) as phosphate binders in dialysis patients.
    Fournier A; Oprisiu R; Albu AT; Dungaciu M; El Esper N; Mornière P
    Am J Kidney Dis; 2000 Jun; 35(6):1248-50. PubMed ID: 10877727
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.